Dedn6526A
Malignant Melanoma
Genentech, Inc.Phase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
450 Active assets in the Malignant Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gm-Csf Ultimovacs ASA | Phase 4 | BBB |
Sargramostim Mayo Clinic | Phase 3 | BBB |
Cediranib M.D. Anderson Cancer Center | Phase 3 | BBB |
Ifa Craig L Slingluff, Jr | Phase 2 | BB |
Tebentafusp Immunocore Ltd | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →